Semmelweis University

Algernon NeuroScience Launches Phase 2a Trial of DMT for Stroke Recovery with Leading Neurologist

3 months ago

• Algernon NeuroScience appoints Dr. Sándor Nardai to lead a groundbreaking Phase 2a clinical trial investigating DMT as a potential stroke recovery treatment, set to begin in Q3 2025. • The 40-patient randomized trial will evaluate DMT's safety profile and monitor key indicators including lesion volume, motor function, and cognitive improvements in stroke patients. • Preclinical studies showed promising results with sub-hallucinogenic DMT doses, demonstrating near-complete motor function recovery and reduced infarct volumes in rat models.

KalVista's Sebetralstat Shows Consistent Efficacy for Hereditary Angioedema

9 months ago

• KalVista Pharmaceuticals presented data at the Bradykinin Symposium 2024, highlighting sebetralstat's consistent efficacy and safety in treating hereditary angioedema (HAE) attacks. • Clinical trials showed sebetralstat provided rapid symptom relief, with a median time to relief of 1.8 hours for all attacks and 1.3 hours for laryngeal attacks. • The oral administration of sebetralstat may offer advantages over current injectable treatments, potentially improving patient compliance and earlier treatment initiation. • Sebetralstat demonstrated a safety profile comparable to placebo, reinforcing its potential as a transformative on-demand treatment for HAE.